Diamox®
Acetazolamide · oral tablet
Antiglaucoma
Approved uses
Chronic simple (open-angle) glaucoma
250 mg to 1 g per 24 hours as an adjunct to the usual therapy, usually in divided doses for amounts over 250 mg
Secondary glaucoma, and preoperative acute angle-closure glaucoma where delay of surgery is desired
250 mg every four hours (preferred); some cases have responded to 250 mg twice daily on short-term therapy; in some acute cases an initial 500 mg followed by 125 mg or 250 mg every four hours may be more satisfactory
OFF-LABELNot in the FDA label for this product
Idiopathic intracranial hypertension with mild visual loss
Titrated to the maximally tolerated dosage, up to 4 g/day PO, added to a low-sodium weight-reduction diet, for 6 months (IIHTT regimen)
RCT · n=165 · modest benefit
Multicenter randomized, double-masked, placebo-controlled trial, N=165 (86 drug, 79 placebo), all on a low-sodium weight-reduction diet. Improvement in perimetric mean deviation was 1.43 dB versus 0.71 dB with placebo; the 0.71 dB difference has a 95% CI that reaches zero (0 to 1.43 dB, P=.050). Papilledema grade (treatment effect -0.70, 95% CI -0.99 to -0.41, P<.001) and NEI VFQ-25 vision-related quality of life (treatment effect 6.35, 95% CI 2.22 to 10.47, P=.003) improved more clearly. The authors call the visual field benefit modest and state that its clinical importance remains to be determined.
Chronic cystoid macular edema in retinitis pigmentosa
500 mg/day PO, the dose that outperformed 250 mg/day in the crossover trial below
Crossover · n=12 · low quality
Masked, placebo-controlled crossover trial in 12 patients treated in 2-week periods: 10 of 12 had both subjective and objective visual acuity improvement, 6 of 12 had less angiographic leakage, and 500 mg/day was more effective than 250 mg/day. A 2022 systematic review and meta-analysis (32 studies reviewed, 7 pooled) concluded that oral and topical carbonic anhydrase inhibitors and local steroids do reduce central macular thickness in this setting, but rated the overall quality of evidence poor because of inferior study designs and small patient numbers.
Contraindications
- Depressed sodium and/or potassium blood serum levels
- Marked kidney and liver disease or dysfunction
- Suprarenal gland failure
- Hyperchloremic acidosis
- Cirrhosis, because of the risk of development of hepatic encephalopathy
- Long-term administration in chronic non-congestive angle-closure glaucoma, since it may permit organic closure of the angle to occur while the worsening glaucoma is masked by lowered intraocular pressure
250 mg tablets, bottles of 10, 30, and 100
Carbonic anhydrase inhibitor: blocks the enzyme that catalyzes reversible hydration of carbon dioxide, and in the eye this decreases aqueous humor secretion and lowers IOP. Renal inhibition causes loss of bicarbonate, which carries out sodium, potassium, and water, alkalinizing the urine and promoting diuresis.
Warnings & Precautions
- Severe sulfonamide reactions: Fatalities have occurred, although rarely, due to severe reactions to sulfonamides including Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia, and other blood dyscrasias; if signs of hypersensitivity or other serious reactions occur, discontinue use.
- Cross-sensitization: Sensitization may recur whenever any sulfonamide is readministered, irrespective of route.
- Hematologic reactions: Baseline CBC and platelet count before starting and at regular intervals during therapy; discontinue early if significant changes occur.
- Serum electrolytes: Periodic monitoring recommended.
- Anorexia, tachypnea, lethargy, coma and death: Caution is advised with concomitant high-dose aspirin, as these have been reported.
- Acidosis: Use with caution in pulmonary obstruction or emphysema where alveolar ventilation may be impaired, since acetazolamide may precipitate or aggravate acidosis.
- Drowsiness and paresthesia: Increasing the dose does not increase diuresis, often decreases it, and may increase the incidence of drowsiness and/or paresthesia.
- Sulfonamide derivative reactions: Precaution is advised for early detection of reactions common to all sulfonamide derivatives; if they occur, discontinue the drug and institute appropriate therapy.
- High altitude pulmonary or cerebral edema: Gradual ascent is desirable, and use during rapid ascent does not obviate the need for prompt descent if severe forms of high altitude sickness occur.
Common Side Effects
Reactions, occurring most often early in therapy, include paresthesias (particularly tingling in the extremities), hearing dysfunction or tinnitus, loss of appetite, taste alteration, nausea, vomiting, diarrhea, polyuria, and occasional drowsiness and confusion. Metabolic acidosis and electrolyte imbalance may occur. Transient myopia has been reported and invariably subsides upon diminution or discontinuance of the medication. Other occasional reactions include urticaria, melena, hematuria, glycosuria, hepatic insufficiency, flaccid paralysis, photosensitivity, and convulsions. Reactions common to all sulfonamides may occur, including anaphylaxis, fever, rash, crystalluria, renal calculus, bone marrow depression, thrombocytopenic purpura, hemolytic anemia, leukopenia, pancytopenia, and agranulocytosis. Fatalities from severe sulfonamide reactions have occurred, although rarely.
Pregnancy: Teratogenic (limb defects) in mice, rats, hamsters, and rabbits; no adequate and well-controlled studies in pregnant women; use only if the potential benefit justifies the potential risk to the fetus.
Lactation: Potential for serious adverse reactions in nursing infants; decide whether to discontinue nursing or the drug, weighing its importance to the mother.
Safety and effectiveness in pediatric patients have not been established.